N/A N=102 Suppression of HIV 1 RNA in People Living With HIV
HIV
Primary: Undetectable Viral Loads During Treatment — 70.4; 42.5 percentage of blood samples undetectable — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=31,983 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
Influenza
Primary: Occurrences of Culture- or Polymerase Chain Reaction (PCR)-Confirmed Influenza Caused by Any Influenza Viral Types/Subtypes, in Association With a Protocol-defined…
Phase 2 N=30 Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant
Allogeneic Stem Cell Transplant · Viral Infection
Primary: Number of Participants With Presence of a Toxicity — 0 Participants
N/A N=704 Optimizing Viral Load Suppression in Kenyan Children on Antiretroviral Therapy
Chronic HIV Infection
Primary: Number of Participants With Viral Suppression — 289; 283 participants — p=0.55
N/A N=37 PREVAIL VII: Cataract Surgery in Ebola Survivors
Cataract
Primary: Proportion of EVD Survivors With Evidence of Persistence of Ebola Viral RNA in Ocular Tissue — 0 Participants
N/A N=88 Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19
COVID 19
Primary: Change in Viral Load in the Nasopharynx Over the Course of COVID-19 Infection — .116; .071; .118 Log10 copies/mL/days
N/A N=284 Evaluating the Non-Inferiority of Airmod to Capnostream™35
Respiratory Rate
Primary: Test of the Difference Between airRR and mancRR — 0.422; 14.362; 14.784 breaths per minute — p=<0.001
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
Phase 2 N=189 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Respiratory Syncytial Virus
Primary: Time-Weighted Average Change in Nasal Respiratory Syncytial Virus (RSV ) Viral Load From Baseline (Day 1) to Day 9 — -1.26; -0.91 log10 copies/mL — p=0.040
N/A N=360 Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
Viral Infection · Acute Respiratory Infection · Upper Resp Tract Infection
Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants
Phase 2 N=15 Enhancement by Poly-ICLC During HIV-1 Infection
HIV-1 Infected Adults With Chronic HIV-1 Infection
Primary: Number Participants With Adverse Events — 11; 3 Participants
N/A N=178 Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
Phase 2 N=29 Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)
Cystic Fibrosis
Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
Phase 4 N=16 Fluoxetine to Reduce Intubation and Death After COVID19 Infection
COVID-19 · Cytokine Storm
Primary: Number of Outpatient Subject Hospitalizations — 0; 0 Participants